Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Molecular Cancer Therapeutics
Chengfei LiuAllen C Gao

Abstract

Activation of the androgen receptor (AR) and its splice variants is linked to advanced prostate cancer and drives resistance to antiandrogens. The roles of AR and AR variants in the development of resistance to androgen deprivation therapy (ADT) and bicalutamide treatment, however, are still incompletely understood. To determine whether AR variants play a role in bicalutamide resistance, we developed bicalutamide-resistant LNCaP cells (LNCaP-BicR) and found that these resistant cells express significantly increased levels of AR variants, particularly AR-V7, both at the mRNA and protein levels. Exogenous expression of AR-V7 in bicalutamide-sensitive LNCaP cells confers resistance to bicalutamide treatment. Knockdown of AR-V7 in bicalutamide- and enzalutamide-resistant CWR22Rv1, enzalutamide-resistant C4-2B (C4-2B MDVR), and LNCaP-BicR cells reversed bicalutamide resistance. Niclosamide, a potent inhibitor of AR variants, significantly enhanced bicalutamide treatment. Niclosamide and bicalutamide combination treatment not only suppressed AR and AR variants expression and inhibited their recruitment to the PSA promoter, but also significantly induced apoptosis in bicalutamide- and enzalutamide-resistant CWR22Rv1 and C4-2B MDVR cel...Continue Reading

References

Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H I Scher, W K Kelly
Jan 1, 1996·Urology·G J Kolvenbag, G R Blackledge
Jun 5, 2002·Nature Reviews. Cancer·Samuel R Denmeade, John T Isaacs
Jan 30, 2004·Expert Review of Anticancer Therapy·Yves Fradet
Apr 19, 2005·Proceedings of the National Academy of Sciences of the United States of America·Casey E BohlJames T Dalton
Aug 10, 2006·Journal of Cancer Research and Clinical Oncology·William A SeeUNKNOWN CASODEX Early Prostate Cancer Trialists' Group
Dec 30, 2008·Urologic Oncology·Xin Yuan, Steven P Balk
Feb 26, 2009·Molecular Cancer Therapeutics·Siting FengAllen C Gao
Sep 9, 2010·Proceedings of the National Academy of Sciences of the United States of America·Philip A WatsonCharles L Sawyers
Aug 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elahe A MostaghelR Bruce Montgomery
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Nov 19, 2013·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Leslie WilsonSandy Srinivas
Jan 23, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ziyang YuSteven P Balk
Feb 22, 2014·Cancer Research·Maria Thadani-MuleroParaskevi Giannakakou
Apr 18, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chengfei LiuAllen C Gao
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Sep 4, 2014·The New England Journal of Medicine·Emmanuel S AntonarakisJun Luo
Jan 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F PensonCelestia S Higano
May 20, 2016·Molecular Cancer Therapeutics·Stefan PrekovicChristine Helsen
Oct 25, 2016·The Journal of Urology·Xichun LiuHaitao Zhang

❮ Previous
Next ❯

Citations

Apr 1, 2018·ChemMedChem·Hachemi KadriYoucef Mehellou
Apr 6, 2019·Anti-cancer Agents in Medicinal Chemistry·Elena V TretyakovaUsein M Dzhemilev
Jul 10, 2019·Anti-cancer Agents in Medicinal Chemistry·Mahdi HatamipourAmirhossein Sahebkar
Mar 4, 2020·International Journal of Oncology·Romina Gabriela ArmandoDaniel Eduardo Gomez
Dec 20, 2018·Medicinal Research Reviews·N G R Dayan ElshanMichael E Jung
Aug 23, 2019·Current Molecular Pharmacology·Mahdi HatamipourAmirhossein Sahebkar
Nov 3, 2020·Frontiers in Oncology·Daisuke ObinataSatoshi Inoue
Aug 4, 2020·Asian Journal of Urology·Dhirodatta SenapatiHannelore V Heemers
Feb 12, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Justyna PacułtMarian Paluch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis